Difference between revisions of "25I-NBOH"

Revision as of 14:23, 19 April 2014

Safety profile
Category: Psychedelic
Main effects: Open and closed eye visuals, euphoria, change in perception of time
Side effects: Nausea, vasoconstriction (mostly when combined with other vasoconstricting substances like LSD), unusual body sensations (facial flushing, chills, goosebumps, body energy), slight increase in heart rate, difficulty focusing
Health risks: paranoia, fear, and panic, dystonia (rare), seizure (rare), death (rare)
Important safety remarks: 25I-NBOH is a very new substance, with little known about its pharmacological or behavioral risks. The LD50 (median lethal dose) is not known. Elaborate studies on this substance have not been performed, so long term effects are UNKNOWN! Warning: This chemical is active in the microgram (µg) range! Please use extreme caution if working with this substance, a milligram scale and liquid measurement are VITAL! Please start with doses of 500µg or less!

25I-NBOH (NBOH-2CI, Cimbi-27) is a derivative of the phenethylamine derived hallucinogen 2C-I. It acts as a potent agonist for the 5HT2A receptor, with a Ki of 0.061nM at the human 5HT2A receptor, similar to the better-known compound 25I-NBOMe, making it some twelve times the potency of 2C-I itself. In vitro tests showed this compound acted as an agonist but animal studies have not been reported. While the N-benzyl derivatives of 2C-I were significantly increased in binding activity to 5HT2A receptor fragments, compared to 2C-I, the N-benzyl derivatives of DOI were less active, compared to DOI.

It was discovered in 2006 by a team at Purdue University.

Links

• bluelight.org: The Big Dandy 25I-NBOH Thread
• isomerdesign.com: 25I-NBOH

Reference